Lentiviral Vectors | CHOP Research Institute

Cornerstone Blog

Building on Nature's Delivery System to Advance Gene Therapy

Published on

Nov 5, 2021

Raymond G. Perelman Center for Cellular and Molecular Therapeutics

The Clinical Vector Core, an award-winning, state-of-the-art, multi-product GMP manufacturing facility, supports the growing field of gene therapy.

Cornerstone Blog

CCMT Facility Honored, Autistic Drivers, Predicting EoE Milk Allergy, Minority Trainee Development Scholarship, PAS Preview

Published on

Apr 30, 2021

This week’s news round-up highlights the CCMT’s state-of-the-art Clinical Manufacturing Facility

Cornerstone Blog

Will a New Vector Offer Safer Gene Therapy for Red Blood Disorders?

Published on

Feb 1, 2021

Snapshot Science: Will a New Vector Offer Safer Gene Therapy for Red Blood Disorders?

CHOP researchers have developed a potentially safer and more effective gene therapy vector for red blood disorders.

Research Vector Core

The Research Vector Core provides state-of-the-art technology support for investigators requiring viral-based vectors for gene transfer in basic research and pre-clinical studies.

Stefano Rivella, PhD

Dr. Rivella is an expert in the pathophysiology of erythroid and iron disorders and in the generation of lentiviral vectors for the cure of hemoglobinopathies. He also investigates additional disorders such as anemia of inflammation and hemochromatosis.

E-mail:

rivellas [at] chop.edu